瑞戈非尼杂质14 | 835621-12-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 瑞戈非尼杂质14
• 英文名称: N-Desmethyl regorafenib N-oxide
• 英文别名: 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]-3-fluorophenoxy]-1-oxidopyridin-1-ium-2-carboxamide
• CAS: 835621-12-0
• 化学式: C20H13ClF4N4O4
• 分子量: 484.8
• InChiKey: JPEWXTSDCNCZOD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  33
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  119
• 氢给体数：
  3
• 氢受体数：
  8

文献信息

• DRUG COMBINATIONS WITH FLUORO-SUBSTITUTED OMEGA-CARBOXYARYL DIPHENYL UREA FOR THE TREATMENT AND PREVENTION OF DISEASES AND CONDITIONS
  申请人：Christensen Olaf

  公开号：US20130183268A1

  公开（公告）日：2013-07-18

  The present invention relates to drug combinations and pharmaceutical compositions for treating hyperproliferative disorders such as cancer including non-small cell lung carcinoma, said drug combination comprising (1) a fluoro-substituted-diaryl urea of Formula (I), (2) at least one antifolate and optionally (3) at least one platinum complex antineoplastic nucleic acid binding agent, where any of these components can be present in the form of a pharmaceutically acceptable salt or other derivative thereof.

  本发明涉及用于治疗增殖过度疾病，如癌症（包括非小细胞肺癌）的药物组合和制药组合物，其中所述药物组合包括（1）式（I）的氟代二芳基脲，（2）至少一种抗叶酸药物，可选地（3）至少一种铂类抗肿瘤核酸结合剂，其中这些任何成分均可以以药学上可接受的盐或其他衍生物的形式存在。
• Combination of regorafenib and acetylsalicylic acid for treating cancer
  申请人：BAYER PHARMA AKTIENGESELLSCHAFT

  公开号：US10898500B2

  公开（公告）日：2021-01-26

  The present invention relates to pharmaceutical compositions and combinations comprising regorafenib and acetylsalicylic acid, or a hydrate, solvate, metabolite or pharmaceutically acceptable salt thereof or a polymorph thereof for treating, preventing or managing diseases and conditions including hyperproliverative disorders such as cancer in humans and other mammals.

  本发明涉及包含瑞戈非尼和乙酰水杨酸或其水合物、溶液剂、代谢物或药学上可接受的盐或其多晶型物的药物组合物和组合物，用于治疗、预防或控制疾病和病症，包括人类和其他哺乳动物的肝功能亢进性疾病，如癌症。
• COATED PHARMACEUTICAL COMPOSITION CONTAINING REGORAFENIB
  申请人：Bayer HealthCare LLC

  公开号：EP2892507B1

  公开（公告）日：2017-02-01
• COMBINATION OF REGORAFENIB AND ACETYLSALICYLIC ACID FOR TREATING COLORECTAL CANCER
  申请人：Bayer Pharma Aktiengesellschaft

  公开号：EP2900269B1

  公开（公告）日：2018-08-01
• COMBINATION OF REGORAFENIB AND PD-1/PD-L1(2) INHIBITORS FOR TREATING CANCER
  申请人：Bayer Aktiengesellschaft

  公开号：EP3630112A1

  公开（公告）日：2020-04-08